Federal Register Notice: FDA will hold a public meeting 10/25 from 9 a.m. to 12:30 p.m. on the agency’s patient-focused drug development initiative. This effort provides for a more systematic approach under PDUFA V for obtaining patient perspective on the disease severity and the currently available treatments for a set of disease areas. The public is invited to comment by 11/1 on a preliminary list of nominated disease areas for the patient-focused drug development initiative and the criteria used for nomination. The meeting will be held at the FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. Contact Andrea Tan, (301) 796-7641. To view this notice, click here.